Loading clinical trials...
Loading clinical trials...
A Phase II Study With a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15
Conditions
Interventions
Vosaroxin
Azacitidine
Locations
3
Germany
Kliniken Essen-Süd, Evang. Krankenhaus Essen-Werden gGmbH
Essen, Germany
Klinikum Oldenburg, Klinik für Innere Medizin II
Oldenburg, Germany
University Hospital Ulm
Ulm, Germany
Start Date
April 19, 2018
Primary Completion Date
October 31, 2019
Completion Date
October 31, 2019
Last Updated
October 28, 2020
NCT06285890
NCT06220162
NCT04065399
NCT06484062
NCT04628026
NCT06994676
Lead Sponsor
University of Ulm
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions